Organization
Zhejiang Genfleet Therapeutics
8 clinical trials
Clinical trial
A Phase I Study With Single/Multiple Dose Administered to Explore the Safety/Tolerability and Pharmacokinetics of GFH018 in the Treatment of Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-08-11
Clinical trial
A Phase Ib/II, Multicentre, Open-label Study to Assess the Efficacy, Safety/ Tolerability and Pharmacokinetic of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Multi-center, Single-arm, and Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH018 in Combination With Toripalimab in the Treatment of Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2023-12-31
Clinical trial
A Phase Ib/II, Multicenter, Open-label, Single-arm Study to Assess the Safety and Efficacy of GFH009 in Combination With Zanubrutinib in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Single-dose and Multiple-dose Study Evaluating the Pharmacokinetics and Safety of GFH312 in Healthy Chinese SubjectsStatus: Completed, Estimated PCD: 2023-02-13
Clinical trial
A Double-blinded, Randomized, Placebo-controlled Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)Status: Withdrawn, Estimated PCD: 2023-12-31
Clinical trial
A Phase 2 Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy for Patients With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C MutationStatus: Recruiting, Estimated PCD: 2025-03-01